Business context and reporting period
Registrant identity: The supplied filing is Access Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended September 30, 2012; it does not identify Abeona Therapeutics, Inc. Investors should verify the company and filing identity.
Access was an emerging biopharmaceutical company developing drug-delivery technologies. MuGard, its marketed oral-mucositis product, was its principal commercial product; ProLindac was in Phase 2 development. Some programs were on hold or reliant on partners and funding. The company terminated its Thiarabine license and stopped development during the third quarter.
Key financial results and liquidity
| Metric | Q3 2012 / September 30, 2012 | Comparable period |
|---|---|---|
| Revenue | $871,000 | $1,041,000 in Q3 2011 |
| MuGard U.S. product sales | $781,000 | $82,000 in Q3 2011 |
| Operating loss | $956,000 | $1,784,000 in Q3 2011 |
| Net loss attributable to common stockholders | $15,311,000; $0.63 per share | $97,000; approximately $0.00 per share in Q3 2011 |
| Cash and cash equivalents | $106,000 | $2,460,000 at December 31, 2011 |
| Working capital deficit | $8,135,000 | $8,877,000 at December 31, 2011 |
| Secured debt | $2,750,000 outstanding; past due | Repaid November 2, 2012, with accrued interest |
For the nine months ended September 30, 2012, revenue was $3.398 million versus $1.341 million in 2011; U.S. MuGard sales were $1.950 million versus $137,000. Net loss attributable to common stockholders was $31.682 million versus $4.140 million, or $1.31 versus $0.21 per share. The 2012 loss included a $25.770 million loss from revaluing the Series A preferred-stock derivative liability, including $13.9 million in Q3; this noncash fair-value item was a major driver of reported losses.
Nine-month operating expenses were $6.495 million, down from $7.527 million. Research and development spending declined to $1.712 million from $2.822 million. Operating cash use was $2.339 million versus $5.645 million in the prior-year period; cash fell by $2.354 million to $106,000. Management reported a net cash burn rate of approximately $231,000 per month.
Material changes, financing, and outlook
- Q3 revenue decreased year over year despite strong MuGard growth, principally because Q3 2011 included $936,000 of licensing revenue, including a one-time amount associated with termination of a Korean license. Q3 2012 licensing revenue was $62,000.
- Nine-month licensing revenue included $706,000 of previously deferred SpePharm fees and a $500,000 termination fee recognized after the parties ended their MuGard agreement. MuGard remained available in Europe through the former partner for up to six months; Access was seeking a replacement partner.
- On October 25, 2012, Access closed a $10 million Series B preferred-stock and warrant financing: $4.703 million was new cash and approximately $5.297 million represented conversion of Series A dividends payable. The transaction included warrants to purchase 20 million common shares at $0.50 per share; Series B terms rank senior to Series A in certain respects.
- Management said existing resources, MuGard revenue, and expected license receipts were expected to fund the current operating level into the fourth quarter of 2013. It also said additional financing would be required and, as of November 14, the company lacked sufficient capital to achieve its long-term goals. Failure to raise funds or secure licensing arrangements could threaten continued operations and going-concern status.
- The filing reports $8.062 million of Series A dividends payable at September 30 and $857,000 of accrued liquidated damages related to registration obligations. The October financing converted approximately $5.297 million of dividend obligations into Series B preferred stock.
Risks, contingencies, and other notable items
- MuGard sales were increasing, but the company had limited product and royalty revenues and a history of operating losses. It had an accumulated deficit of $287.123 million at September 30, 2012.
- The independent auditor’s prior-year report included a going-concern explanatory paragraph. The company stated it might not continue as a going concern without adequate capital or future license agreements.
- Disclosure controls were deemed ineffective because an unremediated material weakness remained: financial reporting depended solely on the CFO, with inadequate segregation of duties and technical accounting resources. Management described interim review measures and planned to add accounting staff when finances allowed.
- A putative class action filed in June 2012 seeks unspecified damages over the Pexiganan license and alleged fiduciary-duty breaches. The company said it considered the claims without merit and intended to defend itself.
- Management cited interim MuGard post-marketing trial results involving 70 patients, including statistically significant delays in oral-mucositis onset and reduced weight loss in one analyzed population. These were interim results, not a substitute for reviewing the full study evidence.
- No formal financial guidance was provided. Product development, clinical results, regulatory approvals, partner activity, financing availability, and potential dilution remain material uncertainties.
Important facts for investors to verify
- Confirm that this Access Pharmaceuticals filing—not an Abeona Therapeutics filing—is the intended document.
- Review the Series B terms, preferred-stock priority, warrant terms, and resulting potential dilution. As of November 14, the filing reported 24,196,734 common shares outstanding; Series A and Series B preferred shares and warrants also carried substantial conversion or exercise potential.
- Reconcile the October financing’s $10 million stated amount with its $4.703 million of new cash proceeds and the noncash conversion of accrued dividends, and assess post-financing liquidity after repayment of the secured note.
- Assess the sustainability and cash contribution of MuGard sales, European commercial arrangements, and anticipated license receipts against the stated fourth-quarter 2013 funding horizon.
- Monitor the preferred-stock derivative valuation and its effect on reported earnings, the accrued dividend and registration-damages obligations, the litigation, and remediation of the control weakness.